Siponimod approved by FDA
Siponimod approved by FDA
FDA approves new oral drug to treat multiple sclerosis in the US
https://www.ms-uk.org/fda-approves-new- ... lerosis-us
The US Food and Drug Administration has approved siponimod (Mayzent) tablets to treat adults with relapsing forms of multiple sclerosis (MS), which will include clinically isolated syndrome, relapsing remitting and active secondary progressive MS (SPMS).
The efficacy of siponimod was shown in a clinical trial of 1,651 patients that compared siponimod to placebo in patients with SPMS who had evidence of disability progression in the prior two years and no relapses in the three months prior to enrolment. The primary endpoint of the study was the time to three-month confirmed progression in disability. The fraction of patients with confirmed progression of disability was statistically significantly lower in the siponimod group than in the placebo group. Siponimod also decreased the number of relapses experienced by these patients. In the subgroup of patients with non-active SPMS, the results were not statistically significant.
Siponimod must be dispensed with a patient Medication Guide that describes important information about the drug's uses and risks. Siponimod may increase the risk of infections, so patients should have a complete blood count taken before treatment is initiated. The drug may cause macular edema (a build-up of fluid in the macula), so patients should contact their consultantif they experience a change in vision. Siponimod may cause short decreases in heart rate and may cause a decline in lung function. Liver enzymes should be checked before initiation of the drug and health care professionals should closely monitor patients with severe liver impairment. Health care professionals should monitor the patient's blood pressure during treatment. Women of childbearing potential should use effective contraception during and for 10 days after stopping the drug due to the potential risk of foetal harm. Health care professionals should monitor patients for posterior reversible encephalopathy syndrome (characterised by headache, confusion, seizures and visual loss) and monitor patients that had treatment with immunosuppressive or immune-modulating therapies because there may be unintended additive immunosuppression with siponimod.
The most common adverse reactions reported by patients receiving siponimod in the clinical trials included headache, high blood pressure and liver function test increases.
For more information on MS drugs available in the UK, click here and download MS-UK’s free Disease Modifying Therapies Choices leaflet.
Source: MS-UK 29/03/19
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1215 Views
-
Last post by frodo
Mon Apr 22, 2019 10:19 am
-
-
Siponimod reduces progression with or without relapses
by frodo » Mon Jul 13, 2020 8:12 am » in MS Etiology and Pathogenesis - 0 Replies
- 248 Views
-
Last post by frodo
Mon Jul 13, 2020 8:12 am
-
-
- 0 Replies
- 301 Views
-
Last post by frodo
Mon Apr 13, 2020 12:20 am
-
- 1 Replies
- 1197 Views
-
Last post by NHE
Thu Jun 13, 2019 12:54 am
-
- 8 Replies
- 1763 Views
-
Last post by EdmontonAlberta
Wed Oct 02, 2019 5:40 pm
-
- 0 Replies
- 6120 Views
-
Last post by NHE
Sat Dec 14, 2019 5:21 am
-
-
Safety vs. eficacy for some approved drugs
by frodo » Fri Jan 17, 2020 3:08 am » in General Discussion - 0 Replies
- 622 Views
-
Last post by frodo
Fri Jan 17, 2020 3:08 am
-
-
-
Review: Eficacy vs. safety for some approved drugs
by frodo » Fri Jan 17, 2020 2:54 am » in Drug Pipeline - 0 Replies
- 820 Views
-
Last post by frodo
Fri Jan 17, 2020 2:54 am
-